
Evolent Health (EVH) Stock Forecast & Price Target
Evolent Health (EVH) Analyst Ratings
Bulls say
Evolent Health is poised for long-term growth, with significant upside expected in 2027 and beyond, driven by strong top-line growth and a conservative posture towards reserves under new CFO Mario Ramos. With a focus on technology and AI initiatives, the company has an attractive growth proposition, with potential cross-selling, upselling, and new contract opportunities. While there are potential downside risks, our outlook remains positive, with a 2027 adjusted EBITDA estimate of $200 million and a target EV/EBITDA multiple of 10x, in line with the company's one-year average.
Bears say
Evolent Health is facing a challenging future due to its 2026 outlook, which is below Street expectations and more heavily weighted towards the second half of the year. This can primarily be attributed to the onboarding of $900 million in revenue from new Performance Suite contracts, as well as membership shifts within large existing customers. Additionally, the company's $15 million overpayment from a payor in the fourth quarter of 2025 will reverse in the first quarter of 2026, contributing to a decrease in projected EBITDA. These factors, combined with regulatory risks and potential challenges in maintaining profitability in at-risk contracts, make for a negative outlook on the company's stock performance.
This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.
Evolent Health (EVH) Analyst Forecast & Price Prediction
Start investing in Evolent Health (EVH)
Order type
Buy in
Order amount
Est. shares
0 shares